Markets move fast. You should move faster. Be the first to know when deals break, stocks move, or biotech headlines hit. Sign up to get breaking news alerts the moment they happen.
Barclays downgrades AST SpaceMobile from Overweight to Underweight, maintaining $60 price target. Stock valuation concerns overshadow promising direct-to-cellular technology prospects.
President Trump signaled major price reductions for Novo Nordisk's Ozempic, potentially lowering costs to $150. This announcement, made amid ongoing drug price negotiations, caused significant drops in pharma stock prices.
Disc Medicine receives FDA's Commissioner's National Priority Voucher for bitopertin, accelerating approval timeline to 1-2 months for EPP patients who suffer severe sun sensitivity.
Shares of Zions Bancorp and Western Alliance tumbled after disclosing loan fraud tied to distressed commercial mortgages. This adds to wider concerns about asset quality, following bankruptcies like Tricolor and First Brands, and raises questions about regional lenders' risk exposure.
President Trump announces new employer-focused IVF initiative to reduce fertility treatment costs. Voluntary program aims to expand workplace coverage options.
Praxis Precision Medicines stock rallied over 170% after its experimental essential tremor treatment ulixacaltamide exceeded expectations in two Phase 3 trials, defying earlier pessimism.
